Biotech | August 08, 2021
TAKE divests stake in Navitas Life Sciences to HIG
The transaction is expected to close in the Q4FY22
The transaction is expected to close in the Q4FY22
Whole-genome sequencing to identify genetic mutation; epidemiological studies to help assess the distribution and mathematical modelling to forecast spread
AstraZeneca, Sinopharm and Moderna were part of the study
It works as an adjunct to standard care based on robust clinical trials
Ayush Ministry will conduct the study along with the UK’s London School of Hygiene and Tropical Medicine
The first quarter performance reflects growth across all its business divisions as the company continued to operate at normal levels
State-of-the-art R&D lab expands technical feasibility capabilities for long-acting delivery of small molecules, biologics, nucleotides
The TWYMEEG approval is supported by numerous preclinical and clinical studies, including the Phase 3 TIMES (Trials of IMeglimin for Efficacy and Safety) program managed jointly by both the companies
The new platform is the latest initiative under Lupin’s long running umbrella programme, Joint Airways Initiative (JAI), for patients suffering from respiratory ailment
These vaccine doses will be manufactured and stockpiled by the company from August-December 2021
Subscribe To Our Newsletter & Stay Updated
